Analysts Offer Predictions for CG Oncology FY2026 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for CG Oncology in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($3.58) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $75.00 target price on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

A number of other research firms have also weighed in on CGON. Scotiabank started coverage on shares of CG Oncology in a research note on Wednesday, April 16th. They issued a “sector perform” rating and a $23.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Monday, April 28th. Morgan Stanley lowered their price objective on shares of CG Oncology from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Monday, May 19th. Royal Bank of Canada increased their price target on shares of CG Oncology from $66.00 to $68.00 and gave the company an “outperform” rating in a research report on Tuesday, April 29th. Finally, JPMorgan Chase & Co. assumed coverage on shares of CG Oncology in a research report on Friday, May 2nd. They set an “overweight” rating and a $41.00 price target for the company. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, CG Oncology currently has an average rating of “Buy” and a consensus target price of $58.22.

CG Oncology Price Performance

NASDAQ:CGON opened at $26.50 on Wednesday. CG Oncology has a 1-year low of $14.80 and a 1-year high of $40.47. The company has a 50-day moving average of $23.83 and a 200 day moving average of $26.94. The firm has a market cap of $2.02 billion, a PE ratio of -17.55 and a beta of 0.86.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.09). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.53 million.

Insider Buying and Selling at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On CG Oncology

Hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new position in shares of CG Oncology during the fourth quarter valued at about $41,000. CWM LLC increased its holdings in shares of CG Oncology by 3,957.7% during the first quarter. CWM LLC now owns 2,110 shares of the company’s stock valued at $52,000 after acquiring an additional 2,058 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of CG Oncology by 1,051.0% during the first quarter. GAMMA Investing LLC now owns 2,302 shares of the company’s stock valued at $56,000 after acquiring an additional 2,102 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of CG Oncology during the fourth quarter valued at about $68,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of CG Oncology during the fourth quarter valued at about $100,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.